Details : Includes glioblastomas and other aggressive forms. 

Research Status : GcMAF crosses the blood-brain barrier and modulate immune responses, 

Research findings : GcMAF (Gc protein-derived macrophage-activating factor) is a type of immunotherapy that has been explored for its potential benefits in treating various cancers, including glioblastomas. Here are 12 possible reasons how GcMAF has benefited glioblastoma patients: 

1. Immune System Activation : GcMAF activates macrophages, which are crucial for attacking cancer cells. 
2. Reduction of Nagalase Activity : Cancer cells produce Nagalase, an enzyme that inhibits the immune system. GcMAF can reduce Nagalase levels, potentially restoring immune function.
3. Anti-Angiogenic Effects : GcMAF inhibits the formation of new blood vessels that tumors need to grow.
4. Enhanced Phagocytosis : Activated macrophages can better engulf and destroy cancer cells.
5. 5. Improved Immune Surveillance : GcMAF can enhance the body’s ability to detect and eliminate cancer cells.
6. Reduction of Tumor Burden : By activating macrophages, GcMAF can help reduce the size and metastasis.
7. Support for Conventional Therapies : GcMAF can enhance the effectiveness of traditional treatments like chemotherapy and radiation.
8. Minimal Side Effects : GcMAF therapy has been reported to have minimal adverse effects and no lasting side effects, compared to conventional cancer treatments. 
9. Potential for Long-Term Remission : Studies suggest that GcMAF can lead to long-term remission in cancer patients.
10. Improved Quality of Life : Patients receiving GcMAF have reported better overall health and fewer cancer-related symptoms. 
11. Reduction in Metastasis : GcMAF can help prevent the spread of cancer to other parts of the body.
12. Personalized Treatment : GcMAF therapy can be tailored to individual patients based on their specific immune profiles.